<DOC>
	<DOC>NCT01096511</DOC>
	<brief_summary>This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.</brief_summary>
	<brief_title>Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)</brief_title>
	<detailed_description />
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Abdominal Abscess</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Patients at least 18 years of age with a diagnosis of cIAI treated with Moxifloxacin infusion with/without sequential tablet treatment can be included into the study. The local Moxifloxacin product information must be considered. Contraindications stated in the local Moxifloxacin product information. Warnings and precautions, stated in the local Moxifloxacin product information must be considered as potential exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Moxifloxacin,</keyword>
	<keyword>cIAI</keyword>
	<keyword>non-interventional</keyword>
</DOC>